Lipocine (LPCN) EPS (Diluted) Growth (3y) (2015 - 2025)
Lipocine (LPCN) EPS (Diluted) Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 61.64% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 36.83% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.90% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.81% |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -8.46% |
| Jun 30, 2025 | 6.41% |
| Mar 31, 2025 | 19.62% |
| Dec 31, 2024 | -48.94% |
| Sep 30, 2024 | 11.24% |
| Jun 30, 2024 | 24.06% |
| Mar 31, 2024 | 43.22% |
| Dec 31, 2023 | 32.00% |
| Sep 30, 2023 | -3.58% |
| Jun 30, 2023 | 32.21% |
| Mar 31, 2023 | 32.08% |
| Dec 31, 2022 | 41.79% |
| Sep 30, 2022 | 39.55% |
| Jun 30, 2022 | 40.38% |
| Mar 31, 2022 | 34.08% |
| Dec 31, 2021 | 43.60% |
| Sep 30, 2021 | 32.92% |
| Jun 30, 2021 | 20.43% |
| Mar 31, 2021 | 31.49% |
| Dec 31, 2020 | 32.71% |